,Name,Term,ES,NES,NOM p-val,FDR q-val,FWER p-val,Tag %,Gene %,Lead_genes
0,prerank,Complement and coagulation cascades,0.6032829258155483,4.600837542318319,0.0,0.0,0.0,37/47,21.27%,C3;VTN;FGB;FGA;A2M;C4A;C5;CLU;F2;C4BPA;PLG;C9;C7;TFPI;F5;SERPIND1;F13A1;PROS1;CFI;F10;C1R;FGG;SERPINC1;SERPINF2;SERPINA1;F9;F13B;CFHR5;C4B;VWF;C8B;MASP1;C1S;SERPINA5;CFH;SERPINE1;CPB2
1,prerank,Systemic lupus erythematosus,0.5484574351654753,3.2692872419577164,0.0,0.0,0.0,19/28,15.72%,C3;H2AC21;H4C1;C4A;C5;H2BC11;H2BC12;H3-3A;C9;C7;MACROH2A1;H2AC11;H2AZ1;C1R;SNRPD3;C4B;C8B;C1S;ACTN1
2,prerank,ECM-receptor interaction,0.4690130343286587,3.1999102200553655,0.0,0.0,0.0,25/36,25.07%,VTN;FN1;RELN;THBS4;COMP;SDC1;AGRN;LAMB1;COL6A1;LAMC1;THBS1;LAMA5;SDC4;HSPG2;VWF;COL6A3;FRAS1;NPNT;THBS3;LAMB2;TNXB;TNC;COL1A1;COL2A1;COL6A2
3,prerank,Neutrophil extracellular trap formation,0.48992562886996094,2.9085928703990214,0.0,0.0,0.0,14/26,8.12%,C3;H2AC21;H4C1;FGB;FGA;C5;ACTB;H2BC11;H2BC12;H3-3A;MACROH2A1;H2AC11;H2AZ1;FGG
4,prerank,Staphylococcus aureus infection,0.5057542148448134,2.763989539565107,0.0,0.0003478933127174333,0.002,15/22,19.75%,C3;C4A;C5;PLG;KRT18;KRT9;CFI;C1R;FGG;KRT19;C4B;MASP1;KRT10;C1S;CFH
5,prerank,Amyotrophic lateral sclerosis,0.25951838421688594,2.575146156129377,0.0,0.0015945110166215694,0.01,59/85,45.88%,ACTB;PFN1;TUBA1C;VCP;TUBB4B;TUBA4A;HSPA5;ATP5F1B;TUBB1;ANG;PSMD14;DNAH8;TUBB;SRSF3;PSMC5;PSMC3;PSMC4;RAC1;PSMD13;PSMC1;TUBB3;PSMC2;PSMC6;PSMB2;PSMA6;HNRNPA1;NDUFA9;TUBA8;PSMA7;GPX3;SRSF7;PSMD12;PSMD11;ATP5F1A;HNRNPA2B1;ACTR1A;PSMA1;PSMA4;PSMD8;PSMB3;PSMA3;PSMA2;PSMD3;KIF5B;PFN2;PSMB1;NDUFS1;PSMD6;PSMD2;PSMD1;DCTN1;CAT;EIF2S1;PSMA5;TPR;TUBB2A;RAB5A;PSMB4;SDHA
6,prerank,Huntington disease,0.2812432785313813,2.5647061005209077,0.0,0.0014909713402175714,0.01,51/71,45.88%,TUBA1C;TUBB4B;TUBA4A;ATP5F1B;TUBB1;PSMD14;DNAH8;TUBB;CLTC;PSMC5;PSMC3;PSMC4;PSMD13;PSMC1;TUBB3;PSMC2;PSMC6;PSMB2;PSMA6;NDUFA9;TUBA8;PSMA7;TGM2;GPX3;PSMD12;AP2M1;PSMD11;ATP5F1A;ACTR1A;PSMA1;PSMA4;AP2B1;PSMD8;AP2A1;PSMB3;PSMA3;PSMA2;PSMD3;KIF5B;PSMB1;HDAC1;NDUFS1;PSMD6;PSMD2;PSMD1;DCTN1;PSMA5;TUBB2A;CLTA;PSMB4;SDHA
7,prerank,Parkinson disease,0.2997740211498642,2.5422818701312737,0.0,0.001413316582914573,0.011,45/61,45.88%,TUBA1C;TUBB4B;TUBA4A;HSPA5;RPS27A;ATP5F1B;TUBB1;UBA1;PSMD14;TUBB;PSMC5;PSMC3;PSMC4;PSMD13;PSMC1;TUBB3;PSMC2;PSMC6;PSMB2;PSMA6;NDUFA9;CALM1;TUBA8;PSMA7;PSMD12;PSMD11;ATP5F1A;PSMA1;PSMA4;PSMD8;PSMB3;PSMA3;PSMA2;PSMD3;KIF5B;PSMB1;NDUFS1;PSMD6;PSMD2;PSMD1;EIF2S1;PSMA5;TUBB2A;PSMB4;SDHA
8,prerank,Prion disease,0.2673163453662868,2.507230056050166,0.001584786053882726,0.0014495554696559723,0.013,52/74,45.88%,C5;HSPA1A;C9;C7;TUBA1C;TUBB4B;TUBA4A;HSPA5;LAMC1;ATP5F1B;TUBB1;PSMD14;TUBB;C8B;HSPA8;PSMC5;PSMC3;PSMC4;RAC1;PSMD13;PSMC1;TUBB3;PSMC2;PSMC6;PSMB2;PSMA6;NDUFA9;TUBA8;PSMA7;PSMD12;PSMD11;ATP5F1A;PSMA1;PSMA4;PSMD8;PSMB3;C6;PSMA3;PSMA2;PSMD3;KIF5B;PSMB1;NDUFS1;PSMD6;PSMD2;PSMD1;EIF2S1;PSMA5;STIP1;TUBB2A;PSMB4;SDHA
9,prerank,PI3K-Akt signaling pathway,0.2644933761701413,2.314421993492133,0.0,0.005914186316196366,0.055,31/62,26.24%,VTN;FN1;RELN;THBS4;HSP90AB1;COMP;HSP90AA1;LAMB1;COL6A1;LAMC1;HSP90B1;THBS1;LAMA5;PPP2CA;IGF2;YWHAZ;VWF;COL6A3;THBS3;YWHAQ;LAMB2;TNXB;RAC1;TNC;COL1A1;YWHAE;COL2A1;PCK2;YWHAG;COL6A2;PPP2R1A
10,prerank,Spinocerebellar ataxia,0.33686178470826783,2.2971117720284657,0.001658374792703151,0.006088132972555083,0.06,28/35,47.75%,RELN;PSMD14;PSMC5;PSMC3;PSMC4;PSMD13;PSMC1;PSMC2;PSMC6;PSMB2;PSMA6;PSMA7;PSMD12;PSMD11;PSMA1;PSMA4;PSMD8;PSMB3;PSMA3;PSMA2;PSMD3;PSMB1;PSMD6;PSMD2;PSMD1;PSMA5;PSMB4;NOP56
11,prerank,mTOR signaling pathway,-0.5229681978798586,-2.2833118249631306,0.0,0.1105725800847752,0.082,13/13,48.16%,PRKAA1;MAPK1;EIF4B;RPS6KA3;SEC13;NRAS;ATP6V1B2;MAP2K1;ATP6V1A;SLC3A2;EIF4E;RPS6;MAPK3
12,prerank,Proteasome,0.3360482281254611,2.2723318570004283,0.003305785123966942,0.006812910707383069,0.07,33/35,61.72%,PSMD14;PSMC5;PSMC3;PSMC4;PSMD13;PSMC1;PSMC2;PSMC6;PSME2;PSMB2;PSMA6;PSMA7;PSMD12;PSMD11;PSMA1;PSMA4;PSMD8;PSMB3;PSMA3;PSMA2;PSMD3;PSMB1;PSMD6;PSMD2;PSMD1;PSMA5;PSMB4;PSMD7;PSME3;PSMB5;PSMB6;PSMB9;PSME1
13,prerank,Neuroactive ligand-receptor interaction,0.7018543114094729,2.222789604073082,0.0,0.009366358419315513,0.099,5/7,3.27%,C3;C5;PARD3;F2;PLG
14,prerank,Coronavirus disease,0.21403063534963737,2.2203847040170235,0.004754358161648178,0.008697332817935834,0.099,69/93,55.17%,C3;FGB;FGA;C4A;C5;F2;C9;C7;F13A1;RPS27A;C1R;FGG;RPSA;RPS10;F13B;C4B;RPL22;VWF;C8B;RPS18;RPLP1;MASP1;RPS9;C1S;RPS16;RPS3;RPS25;RPLP0;RPS13;RPL10A;RPL30;RPS14;RPS2;RPL12;RPS26;RPL27A;RPS4X;RPLP2;RPS5;RPL18;RPS11;CFB;RPL11;RPS3A;RPL5;C6;NRP1;RPS15A;RPS7;RPL14;C2;RPL9;RPS8;RPL15;RPL27;RPL4;RPS23;RPL7;RPL29;RPL13;MAPK3;RPL28;RPL26;RPL8;MASP2;RPS6;RPS17;RPS27;RPS20
15,prerank,Malaria,0.504015762120836,2.1725310149776913,0.0017064846416382253,0.011770390413606495,0.141,9/13,20.81%,HBB;HBA2;THBS4;COMP;SDC1;TGFB1;THBS1;THBS3;LRP1
16,prerank,JAK-STAT signaling pathway,-0.6455399061032864,-2.1526998556718264,0.0021645021645021645,0.1344329789451741,0.17,7/7,35.77%,JAK2;STAT5B;STAT1;STAT3;FHL1;PTPN11;PDGFA
17,prerank,Pancreatic secretion,0.6515086336771474,2.1020160994685098,0.004,0.017992607267104756,0.223,6/7,21.27%,RAP1B;AMY1A;CPA1;RAC1;PLA2G2A;CPB2
18,prerank,Signaling pathways regulating pluripotency of stem cells,-0.5220458553791887,-2.086941676228859,0.011086474501108648,0.12958330438005236,0.243,10/10,48.16%,JAK2;MAPK14;STAT3;MAPK1;CTNNB1;NRAS;BMP4;MAP2K1;INHBE;MAPK3
19,prerank,Amoebiasis,0.35695407756150627,2.0462079693442337,0.0017699115044247787,0.02471065735919416,0.311,20/24,49.09%,FN1;C9;LAMB1;TGFB1;LAMC1;LAMA5;C8B;PRDX1;ACTN1;LAMB2;COL1A1;ACTN4;RAB7A;RAB5C;LAMA3;HSPB1;RAB5A;COL1A2;LAMA2;VCL
20,prerank,Focal adhesion,0.23994332117904021,2.039943193166645,0.0,0.02420757634325474,0.32,26/59,22.56%,VTN;FN1;RELN;ACTB;THBS4;TLN1;COMP;LAMB1;FLNA;COL6A1;LAMC1;RAP1B;THBS1;LAMA5;VWF;COL6A3;ACTN1;FLNB;THBS3;LAMB2;TNXB;RAC1;TNC;COL1A1;PARVB;COL2A1
21,prerank,Human cytomegalovirus infection,-0.3237523050073341,-2.0123535926537794,0.004694835680751174,0.1559655340143145,0.333,20/27,41.20%,B2M;GNAI2;HLA-G;GNB4;ITGB3;SRC;MAPK14;VEGFA;STAT3;MAPK1;PPP3CA;CYCS;GNB2;CTNNB1;NRAS;TAPBP;PRKACA;HLA-C;MAP2K1;CALR
22,prerank,PD-L1 expression and PD-1 checkpoint pathway in cancer,-0.46149789052631773,-2.0121298278800057,0.013071895424836602,0.12477242721145163,0.333,11/13,38.22%,JAK2;MAPK14;STAT1;STAT3;MAPK1;CSNK2B;PPP3CA;NRAS;CSNK2A1;PTPN11;MAP2K1
23,prerank,Prolactin signaling pathway,-0.5220458553791887,-2.0059560992586176,0.004524886877828055,0.10843872327612165,0.345,10/10,48.16%,JAK2;SRC;STAT5B;MAPK14;STAT1;STAT3;MAPK1;NRAS;MAP2K1;MAPK3
24,prerank,Ribosome,0.22550474995951708,1.9755937923809408,0.015748031496062992,0.03611681891237565,0.449,53/63,63.18%,RPS27A;RPSA;RPS10;RPL22;RPS18;RPLP1;RPS9;RPS16;RPS3;RPS25;RPLP0;RPS13;RPL10A;RPL30;RPS14;RPS2;RPL12;RPS26;RPL27A;RPS4X;RPLP2;RPS5;RPL18;RPS11;RPL11;RPS3A;RPL5;RPS15A;RPS7;RPL14;RPL9;RPS8;RPL15;RPL27;RPL4;RPS23;RPL7;RPL29;RPL13;RPL28;RPL26;RPL8;RPS6;RPS17;RPS27;RPS20;RPS12;RPL23;RPS19;RPL35A;RPL7A;RPL17;RPL18A
25,prerank,Pathways of neurodegeneration,0.19437132216584013,1.9652212992191906,0.004846526655896607,0.035876497873985315,0.456,55/87,45.88%,TUBA1C;VCP;TUBB4B;TUBA4A;HSPA5;RPS27A;ATP5F1B;TUBB1;UBA1;PSMD14;DNAH8;TUBB;PSMC5;PSMC3;APP;PSMC4;RAC1;PSMD13;PSMC1;TUBB3;PSMC2;PSMC6;PSMB2;PSMA6;NDUFA9;CALM1;TUBA8;PSMA7;GPX3;PSMD12;CAPN2;PSMD11;ATP5F1A;ACTR1A;PSMA1;PSMA4;PSMD8;PSMB3;PSMA3;PSMA2;PSMD3;KIF5B;PSMB1;NDUFS1;PSMD6;PSMD2;PSMD1;DCTN1;CAT;EIF2S1;PSMA5;TUBB2A;RAB5A;PSMB4;SDHA
26,prerank,Human papillomavirus infection,0.22893331279330711,1.928965818444261,0.010050251256281407,0.04278259429013198,0.53,26/56,26.24%,VTN;FN1;RELN;PARD3;PKM;THBS4;COMP;LAMB1;COL6A1;LAMC1;THBS1;LAMA5;PPP2CA;VWF;COL6A3;THBS3;LAMB2;TNXB;PSMC1;TNC;HLA-A;COL1A1;COL2A1;NOTCH3;COL6A2;PPP2R1A
27,prerank,Cysteine and methionine metabolism,0.40227463342900405,1.9073556285311644,0.005309734513274336,0.0469655972168535,0.575,11/16,30.22%,AHCY;LDHA;SRM;LDHB;MDH2;PHGDH;PSAT1;BHMT;MAT2A;TST;MAT1A
28,prerank,"Growth hormone synthesis, secretion and action",-0.446818968279901,-1.8964924144742104,0.009009009009009009,0.1779137754747511,0.563,10/12,38.22%,GNAI2;JAK2;STAT5B;MAPK14;STAT1;STAT3;MAPK1;NRAS;PRKACA;MAP2K1
29,prerank,Human immunodeficiency virus 1 infection,-0.25758303130674653,-1.896017665465588,0.011655011655011656,0.1559655340143145,0.564,25/37,41.20%,AP1G2;B2M;CUL4A;GNAI2;HLA-G;GNB4;SKP1;MAPK14;AP1S1;CDK1;AP1S2;CUL5;MAPK1;SAMHD1;CUL4B;CUL1;PPP3CA;CYCS;GNB2;NRAS;TAPBP;HLA-C;MAP2K1;RBX1;CALR
30,prerank,Alzheimer disease,0.19752210266243667,1.860791895657862,0.011456628477905073,0.06110821666862742,0.673,49/77,45.88%,GAPDH;APOE;TUBA1C;TUBB4B;TUBA4A;ATP5F1B;TUBB1;PSMD14;TUBB;PSMC5;PSMC3;APP;PSMC4;PSMD13;PSMC1;LRP1;TUBB3;PSMC2;PSMC6;RTN4;PSMB2;PSMA6;NDUFA9;CALM1;TUBA8;PSMA7;PSMD12;CAPN2;LPL;PSMD11;ATP5F1A;PSMA1;PSMA4;PSMD8;PSMB3;PSMA3;PSMA2;PSMD3;KIF5B;PSMB1;NDUFS1;PSMD6;PSMD2;PSMD1;EIF2S1;PSMA5;TUBB2A;PSMB4;SDHA
31,prerank,Legionellosis,0.4244919220998251,1.8566728311486023,0.01303538175046555,0.05990287978353305,0.679,8/13,21.22%,C3;HSPA1A;VCP;EEF1A1;EEF1G;HSPA8;ARF1;HSPD1
32,prerank,Antigen processing and presentation,0.37168740556357716,1.850567987583745,0.010676156583629894,0.059837649787398535,0.69,11/18,26.13%,HSPA1A;HSP90AB1;HSP90AA1;HSPA5;CTSB;PDIA3;HSPA8;HLA-A;PSME2;CD74;HSPA4
33,prerank,Relaxin signaling pathway,-0.3474139331134612,-1.78166443592506,0.009216589861751152,0.26343432237741177,0.769,16/18,53.83%,GNAI2;MMP2;GNB4;SRC;MAPK14;VEGFA;ARRB1;MAPK1;GNB2;NRAS;PRKACA;COL3A1;MAP2K1;MAPK3;COL1A2;GNB1
34,prerank,Kaposi sarcoma-associated herpesvirus infection,-0.29885227560054645,-1.7453675308643073,0.016166281755196306,0.28946737544298523,0.824,17/24,39.86%,HLA-G;GNB4;JAK2;SRC;MAPK14;STAT1;VEGFA;STAT3;MAPK1;PPP3CA;CYCS;GNB2;CTNNB1;NRAS;HLA-C;MAP2K1;ICAM1
35,prerank,Adipocytokine signaling pathway,-0.45793224867289317,-1.7275928418061461,0.02412280701754386,0.29002817417451565,0.841,7/10,23.20%,ACSL4;ACSL1;JAK2;PRKAA1;STAT3;PRKAG1;PCK1
36,prerank,Morphine addiction,-0.5305706464681308,-1.7239600028238657,0.015283842794759825,0.27090282120769926,0.849,6/7,32.44%,GNAI2;GNB4;ARRB1;GNB2;PDE2A;PRKACA
37,prerank,RNA degradation,-0.3089034412056588,-1.7209636263850356,0.026004728132387706,0.2544512328752479,0.855,18/21,54.30%,SKIV2L;EXOSC6;TTC37;WDR61;XRN2;PNPT1;PFKP;PABPC4;DCPS;EXOSC4;LSM6;MTREX;ENO2;LSM3;PABPC1;ENO3;DDX6;PFKL
38,prerank,C-type lectin receptor signaling pathway,-0.442622488901506,-1.7164056306923086,0.02494802494802495,0.2408486951169878,0.857,8/10,35.24%,RRAS;SRC;MAPK14;STAT1;MAPK1;PPP3CA;NRAS;PTPN11
39,prerank,Circadian rhythm,-0.6154747948417351,-1.709220496990558,0.025423728813559324,0.23309475829801032,0.868,5/5,38.69%,PRKAA1;SKP1;PRKAG1;CUL1;RBX1
40,prerank,Cholesterol metabolism,0.32026199613700057,1.7051085507092114,0.036395147313691506,0.1275162796229669,0.917,20/22,59.91%,APOB;APOE;APOA1;APOH;ANGPTL8;APOC3;APOC2;PLTP;LRP1;LCAT;LPL;LDLR;APOA4;APOC1;ANGPTL4;ANGPTL3;APOA2;LRP2;PCSK9;SCARB1
41,prerank,Ubiquitin mediated proteolysis,-0.2815940324163964,-1.7028983644904039,0.026200873362445413,0.22492790633034535,0.875,14/24,29.28%,CUL4A;UBE2Z;NEDD4;UBE2I;UBA6;SKP1;CUL5;CUL3;CUL4B;CUL1;CUL2;UBE2D2;SAE1;UBE2M
42,prerank,Pertussis,0.35039325259745935,1.6980617667521907,0.028985507246376812,0.12807627883004769,0.925,10/17,26.18%,C3;C4A;C5;C4BPA;C1R;C4B;C1S;CFL1;SERPING1;CALM1
43,prerank,cGMP-PKG signaling pathway,-0.32040725337884557,-1.6974710972406155,0.03644646924829157,0.21826958842740762,0.878,17/19,57.45%,PPP1R12A;GNAI2;PPP1CC;PDE5A;MAPK1;SLC25A31;PPP3CA;PDE2A;MYLK;MAP2K1;PPP1CB;PPP1CA;MAPK3;MYLK2;KNG1;ATP1A1;VASP
44,prerank,Alcoholism,0.3040957264539185,1.6954378498215918,0.027777777777777776,0.12496203545198521,0.927,8/23,7.07%,H2AC21;H4C1;H2BC11;H2BC12;H3-3A;MACROH2A1;H2AC11;H2AZ1
45,prerank,Cholinergic synapse,-0.41117647058823525,-1.6920041077721006,0.03036876355748373,0.21176912267698175,0.886,11/11,59.21%,GNAI2;GNB4;JAK2;MAPK1;GNB2;NRAS;PRKACA;MAP2K1;MAPK3;GNB1;ACHE
46,prerank,Estrogen signaling pathway,0.30528891943964426,1.6825192130167397,0.030797101449275364,0.12887047971955268,0.943,10/23,15.31%,HSPA1A;KRT18;HSP90AB1;HSP90AA1;KRT9;HSP90B1;KRT19;CTSD;HSPA8;KRT10
47,prerank,Glycolysis / Gluconeogenesis,0.255327375319834,1.6692344868119982,0.026981450252951095,0.1330981832238114,0.955,21/33,39.98%,GAPDH;PKM;PGK1;ENO1;LDHA;PGAM1;ALDOC;AKR1A1;TPI1;LDHB;ALDOA;ADH5;PCK2;ALDH9A1;PGM1;GALM;BPGM;ALDH7A1;ALDH2;GPI;PKLR
48,prerank,Glutamatergic synapse,-0.464474456840869,-1.6639510086051488,0.03805496828752643,0.23272312007870416,0.906,8/8,53.83%,GNAI2;GNB4;MAPK1;PPP3CA;GNB2;PRKACA;MAPK3;GNB1
49,prerank,Th1 and Th2 cell differentiation,-0.4883143365858331,-1.6510210562800867,0.03070175438596491,0.23650892919185604,0.92,6/8,25.48%,JAK2;STAT5B;MAPK14;STAT1;MAPK1;PPP3CA
50,prerank,Aminoacyl-tRNA biosynthesis,0.30562507039951153,1.6348356224326797,0.03180212014134275,0.15284861029714328,0.973,18/21,56.05%,VARS1;RARS1;AARS1;HARS1;DARS1;SARS1;TARS1;IARS1;NARS1;QARS1;GARS1;FARSB;KARS1;EPRS1;WARS1;MARS1;IARS2;LARS1
51,prerank,Arginine and proline metabolism,0.3564706783092021,1.6318614174249202,0.06690777576853527,0.1502464244298415,0.973,11/15,39.16%,OAT;SRM;P4HA1;PYCR1;ALDH9A1;CKB;LAP3;CNDP2;ALDH7A1;ALDH2;P4HA2
52,prerank,mRNA surveillance pathway,-0.27158179220338263,-1.6030177256888376,0.06635071090047394,0.28649106088130477,0.949,20/25,52.31%,CSTF2;CPSF1;UPF1;PABPC4;PPP2R5D;GSPT1;PABPN1;PPP1CC;FUS;NCBP1;DDX19A;NUDT21;PPP2R2A;ALYREF;CPSF6;PPP1CB;PABPC1;PPP1CA;CSTF3;MAGOH
53,prerank,Pentose and glucuronate interconversions,0.4342488225396954,1.6009297936678135,0.04204753199268738,0.16978247882770495,0.984,7/9,35.59%,UGDH;UGP2;DCXR;AKR1A1;SORD;AKR1B1;CRYL1
54,prerank,Hedgehog signaling pathway,-0.582063305978898,-1.5978309673628723,0.03537735849056604,0.28018774360237775,0.951,5/5,42.02%,ARRB1;CUL3;CUL1;PRKACA;LRP2
55,prerank,Acute myeloid leukemia,-0.5208211143695015,-1.5924044247634421,0.04308390022675737,0.2747361726683042,0.953,6/6,48.16%,STAT5B;STAT3;MAPK1;NRAS;MAP2K1;MAPK3
56,prerank,Metabolism of xenobiotics by cytochrome P450,0.37529840916903856,1.586692778934378,0.0647985989492119,0.1776302326110189,0.988,11/13,47.87%,GSTA5;GSTO1;ADH5;GSTP1;EPHX1;AKR7A2;CBR1;GSTM3;GSTA1;GSTM2;CBR3
57,prerank,Phagosome,0.21823095270522724,1.5863803149735003,0.049403747870528106,0.17282842785355346,0.988,19/41,26.83%,C3;ACTB;THBS4;TUBA1C;COMP;TUBB4B;TUBA4A;THBS1;C1R;TUBB1;TUBB;DYNC1H1;THBS3;RAC1;HLA-A;TUBB3;CORO1A;MRC2;TUBA8
58,prerank,Calcium signaling pathway,-0.3838068011199201,-1.5808295563783963,0.04246284501061571,0.27614046973803075,0.961,10/11,52.43%,PDGFC;VEGFA;SLC25A31;PPP3CA;ASPH;PRKACA;MYLK;PDGFA;MYLK2;MST1
59,prerank,ErbB signaling pathway,-0.5208211143695015,-1.5605216216098412,0.0525164113785558,0.2915391564172052,0.968,6/6,48.16%,SRC;STAT5B;MAPK1;NRAS;MAP2K1;MAPK3
60,prerank,Necroptosis,0.2749419916247083,1.5585264715660145,0.042105263157894736,0.19276671820641672,0.997,14/25,30.98%,H2AC21;GLUD1;HSP90AB1;HSP90AA1;PPIA;MACROH2A1;H2AC11;H2AZ1;PYGB;FTH1;PYGL;MACROH2A2;PARP1;CAPN2
61,prerank,Hippo signaling pathway,0.2729413550679337,1.5505026899662298,0.06548672566371681,0.19470272359719595,0.998,13/24,28.87%,ACTB;PARD3;AFP;TGFB1;PPP2CA;CCN2;YWHAZ;YWHAQ;SERPINE1;YWHAE;YWHAG;PPP2R1A;CDH1
62,prerank,Various types of N-glycan biosynthesis,0.43680138708735694,1.5140061669475169,0.08992805755395683,0.2252609199845381,0.998,7/8,44.59%,MAN1A1;ALG1;HEXB;MAN2A1;B4GALT1;MGAT2;MGAT1
63,prerank,Dopaminergic synapse,-0.28320418960341476,-1.5133837216596993,0.05470459518599562,0.3438941539316774,0.983,12/19,34.02%,GNAI2;GNB4;PPP2R5D;PPP1CC;MAPK14;SCN1A;ARRB1;COMT;PPP3CA;GNB2;PRKACA;PPP2R2A
64,prerank,Pyrimidine metabolism,-0.39883331167241,-1.4804782055113335,0.07529411764705882,0.379955836595403,0.989,8/9,48.86%,RRM2B;DPYS;PNP;CMPK1;CTPS1;NT5C2;RRM1;DPYD
65,prerank,Choline metabolism in cancer,-0.4043511714055802,-1.4788431788650636,0.08817204301075268,0.36908794683184926,0.989,8/9,48.16%,PDGFC;MAPK1;PCYT1A;NRAS;PDGFA;MAP2K1;LYPLA1;MAPK3
66,prerank,Salivary secretion,0.4644744509742519,1.4775373594926615,0.09191176470588236,0.2575971573845559,0.999,5/7,26.18%,LYZ;DMBT1;AMY1A;CST3;CALM1
67,prerank,Inflammatory mediator regulation of TRP channels,-0.3965354420628685,-1.4743696817970673,0.06263982102908278,0.3643075533319436,0.99,8/9,49.04%,PPP1CC;SRC;MAPK14;PRKACA;IL1RAP;PPP1CB;PPP1CA;KNG1
68,prerank,GnRH secretion,-0.5205158264947245,-1.4694624584185272,0.09108910891089109,0.3589147152155282,0.992,5/5,48.16%,ARRB1;MAPK1;NRAS;MAP2K1;MAPK3
69,prerank,Long-term potentiation,-0.3461038796928959,-1.4627340402108353,0.08874458874458875,0.35664819634135136,0.993,10/12,48.16%,PPP1CC;MAPK1;PPP3CA;RPS6KA3;NRAS;PRKACA;MAP2K1;PPP1CB;PPP1CA;MAPK3
70,prerank,Glycerolipid metabolism,0.36875677159243536,1.4517242007564508,0.08499095840867993,0.280032373405489,0.999,8/11,37.00%,AKR1A1;ALDH9A1;LPL;ALDH7A1;AKR1B1;TKFC;GLA;ALDH2
71,prerank,"Valine, leucine and isoleucine degradation",-0.2743024706700256,-1.4377043470110114,0.08584686774941995,0.385221774894031,0.996,18/19,67.45%,HMGCL;ACAA1;PCCA;ALDH1B1;ACAA2;PCCB;HADHB;HSD17B10;HADHA;HADH;HMGCS1;ACAT2;ABAT;ACADSB;ACAT1;ALDH2;ECHS1;ALDH7A1
72,prerank,Non-homologous end-joining,0.5097165142797107,1.430957798082818,0.09981515711645102,0.2979578945383578,1.0,4/5,30.51%,XRCC5;XRCC6;FEN1;PRKDC
73,prerank,Tight junction,0.1958185719279143,1.4304177413891515,0.08445945945945946,0.29154702081837763,1.0,25/41,43.31%,ACTB;PARD3;TUBA1C;TUBA4A;PPP2CA;MYH9;ACTN1;EZR;ARPC4;RAC1;MYL6;ACTR3;PCNA;HSPA4;PPP2R1A;TUBA8;ACTN4;ARPC2;ROCK2;MYH10;ARPC5;MSN;VASP;MYH14;CDC42
74,prerank,T cell receptor signaling pathway,-0.43427230046948356,-1.425786881817724,0.08315565031982942,0.3937230339669365,0.996,7/7,56.81%,MAPK14;MAPK1;PPP3CA;NRAS;MAP2K1;MAPK3;CDC42
75,prerank,Serotonergic synapse,-0.3589929975473581,-1.424314296719594,0.07407407407407407,0.38433385653615204,0.996,9/10,53.83%,GNAI2;GNB4;MAPK1;GNB2;NRAS;PRKACA;MAP2K1;MAPK3;GNB1
76,prerank,Mitophagy,-0.4042564646192606,-1.4231288540757523,0.08050847457627118,0.37498237986042865,0.996,6/8,33.26%,RRAS;USP15;SRC;CSNK2B;NRAS;CSNK2A1
77,prerank,Apoptosis,0.2423975547070078,1.3980733358300923,0.118491921005386,0.326898355822044,1.0,19/25,53.13%,ACTB;TUBA1C;TUBA4A;CTSB;LMNA;CTSD;SPTAN1;PRF1;TUBA8;PARP1;CTSH;CAPN2;LMNB2;CTSZ;LMNB1;EIF2S1;CTSV;MAPK3;CTSC
78,prerank,"Glycine, serine and threonine metabolism",0.3537257122827835,1.3833595002481205,0.12593984962406016,0.3400657131812911,1.0,8/11,38.81%,SHMT2;PGAM1;PHGDH;PSAT1;BHMT;BPGM;ALDH7A1;SHMT1
79,prerank,Thermogenesis,-0.23903224280267737,-1.376123549976683,0.11085450346420324,0.44083541796956427,0.999,15/21,46.52%,SMARCA4;ACSL4;ACSL1;PRKAA1;MAPK14;PRKAG1;ATP5PO;RPS6KA3;NRAS;PRKACA;ACTL6A;SDHB;COX7A2;NDUFV1;RPS6
80,prerank,Influenza A,-0.26191434334723007,-1.371905465351717,0.13012048192771083,0.4360303079815274,0.999,15/18,56.17%,JAK2;PABPN1;HNRNPUL1;TRIM25;STAT1;MAPK1;SLC25A31;CYCS;DNAJB1;MAP2K1;ICAM1;DNAJC3;MAPK3;XPO1;EIF2S1
81,prerank,Thyroid cancer,-0.34061392619924574,-1.3598964137629304,0.1127659574468085,0.4451694955546047,0.999,9/10,55.82%,TFG;MAPK1;CCDC6;TPM3;CTNNB1;NRAS;MAP2K1;MAPK3;TPR
82,prerank,"Parathyroid hormone synthesis, secretion and action",-0.39052071658086895,-1.3588594679455803,0.1336116910229645,0.4356649187793653,0.999,7/8,48.16%,GNAI2;SLC9A3R1;ARRB1;MAPK1;PRKACA;MAP2K1;MAPK3
83,prerank,Th17 cell differentiation,-0.3158957763657354,-1.3462643028645236,0.1367713004484305,0.44767345910638595,0.999,8/12,33.43%,JAK2;STAT5B;MAPK14;STAT1;STAT3;MAPK1;PPP3CA;IL1RAP
84,prerank,Fatty acid elongation,-0.3728347045215582,-1.3454040471451225,0.15417558886509636,0.43825917621277527,0.999,6/8,37.23%,ACAA2;PPT1;HADHB;ACOT1;HADHA;HADH
85,prerank,Cellular senescence,-0.2367753923620938,-1.342970831887438,0.14977973568281938,0.43272953333928943,0.999,16/22,48.16%,RRAS;HLA-G;RAD50;PPP1CC;MAPK14;CDK1;MAPK1;SLC25A31;PPP3CA;NRAS;HLA-C;MAP2K1;PPID;PPP1CB;PPP1CA;MAPK3
86,prerank,Ascorbate and aldarate metabolism,0.38781405604690655,1.333955640312761,0.14953271028037382,0.4037108620023193,1.0,6/8,37.70%,UGDH;AKR1A1;ALDH9A1;ALDH7A1;ALDH2;RGN
87,prerank,FoxO signaling pathway,-0.29741783759538054,-1.3326319262180744,0.14814814814814814,0.4398000688414756,1.0,11/14,48.16%,PRKAA1;MAPK14;STAT3;PRKAG1;MAPK1;PCK1;NRAS;MAP2K1;PRMT1;USP7;MAPK3
88,prerank,Oxytocin signaling pathway,-0.23532548961149227,-1.324809214461644,0.15333333333333332,0.44236967865016646,1.0,16/22,48.22%,PPP1R12A;GNAI2;PRKAA1;PPP1CC;SRC;PRKAG1;MAPK1;PPP3CA;NRAS;PRKACA;MYLK;MAP2K1;PPP1CB;PPP1CA;MAPK3;MYLK2
89,prerank,Butanoate metabolism,-0.3427395649617872,-1.324358974645242,0.13882863340563992,0.43326345941522093,1.0,10/10,65.98%,HMGCL;BDH2;HADHA;HADH;HMGCS1;ACAT2;ABAT;ACAT1;ALDH5A1;ECHS1
90,prerank,Retrograde endocannabinoid signaling,-0.31860275897800827,-1.3227863671851559,0.141280353200883,0.42627374294924664,1.0,10/11,58.91%,GNAI2;GNB4;MAPK14;MAPK1;GNB2;PRKACA;NDUFV1;MAPK3;GNB1;NDUFS1
91,prerank,Viral carcinogenesis,0.192683120868632,1.3208374095448463,0.153713298791019,0.41558125073528174,1.0,17/37,28.99%,C3;H4C1;H2BC11;H2BC12;PKM;GSN;YWHAZ;ACTN1;YWHAQ;RAC1;PSMC1;HLA-A;HNRNPK;YWHAE;YWHAG;ACTN4;SND1
92,prerank,Epithelial cell signaling in Helicobacter pylori infection,-0.3291925475652162,-1.3076697383506124,0.15991471215351813,0.44330565646081993,1.0,9/10,56.81%,CSK;ATP6AP1;SRC;MAPK14;ATP6V1B2;PTPN11;ATP6V1A;ADAM10;CDC42
93,prerank,Glutathione metabolism,0.24676142805443374,1.3059338553745454,0.16778523489932887,0.4307030241222479,1.0,15/21,48.16%,GSTA5;PRDX6;GSTO1;SRM;G6PD;IDH1;PGD;GPX3;GSTP1;LAP3;GSTM3;GSTA1;GSTM2;IDH2;GSR
94,prerank,Chemokine signaling pathway,-0.2353882109947781,-1.3045529367068642,0.15777262180974477,0.43896829326199244,1.0,12/21,32.44%,GNAI2;GNB4;JAK2;SRC;STAT5B;STAT1;STAT3;ARRB1;MAPK1;GNB2;NRAS;PRKACA
95,prerank,Nicotinate and nicotinamide metabolism,-0.46658851113716293,-1.294925579985042,0.1945031712473573,0.44696976142969175,1.0,5/5,53.54%,PNP;NADSYN1;NAMPT;NT5C2;NNMT
96,prerank,GnRH signaling pathway,-0.3299422600137858,-1.2925945247837825,0.18461538461538463,0.4420342575220624,1.0,9/10,56.81%,MMP2;SRC;MAPK14;MAPK1;NRAS;PRKACA;MAP2K1;MAPK3;CDC42
97,prerank,Tryptophan metabolism,0.31045242334037815,1.2852101233134743,0.16283185840707964,0.4547980286045613,1.0,9/12,44.89%,HAAO;ALDH9A1;ALDH7A1;ECHS1;ALDH2;ACAT1;DLST;CAT;ACAT2
98,prerank,Hepatitis B,-0.23595266028735096,-1.273944772659574,0.17233560090702948,0.4648384543171727,1.0,11/20,30.16%,JAK2;ATP6AP1;SRC;STAT5B;MAPK14;DDX3X;STAT1;STAT3;MAPK1;CYCS;NRAS
99,prerank,African trypanosomiasis,0.35010583069216744,1.2718100411753261,0.1889908256880734,0.4682714987811901,1.0,3/9,1.64%,HBB;HBA2;APOA1
100,prerank,Insulin signaling pathway,-0.19940311175120967,-1.2665716342892124,0.17857142857142858,0.4691724395054601,1.0,19/27,49.68%,FLOT1;PRKAA1;PPP1CC;PRKAG1;MAPK1;PCK1;HK2;NRAS;PRKACA;PRKAR1A;HK1;MAP2K1;GYS1;PPP1CB;EIF4E;RPS6;PPP1CA;MAPK3;FBP1
101,prerank,Apelin signaling pathway,-0.22433296098761718,-1.2646202757052052,0.16129032258064516,0.46330679683187737,1.0,15/21,48.22%,RRAS;GNAI2;GNB4;PRKAA1;PRKAG1;MAPK1;GNB2;NRAS;PRKACA;MYLK;MAP2K1;TFAM;RPS6;MAPK3;MYLK2
102,prerank,Fat digestion and absorption,0.3572267920094006,1.2600682825859322,0.19553072625698323,0.47986664089679165,1.0,9/9,64.47%,APOB;APOA1;PLA2G2A;ACAT1;APOA4;ACAT2;MTTP;SCARB1;FABP1
103,prerank,N-Glycan biosynthesis,0.34332069713726365,1.2594672461047574,0.17454545454545456,0.47141249232588284,1.0,7/9,44.59%,MAN1A1;GANAB;ALG1;MAN2A1;B4GALT1;MGAT2;MGAT1
104,prerank,Base excision repair,0.4592954292152319,1.2560589622230542,0.19548872180451127,0.46763216972436145,1.0,4/5,35.01%,FEN1;PCNA;PARP1;APEX1
105,prerank,Thyroid hormone synthesis,0.29924833337425755,1.2552719514568176,0.20036429872495445,0.46012172619264685,1.0,10/13,48.45%,ALB;HSPA5;HSP90B1;SERPINA7;GPX3;PDIA4;TG;ATP1A1;GSR;TTR
106,prerank,One carbon pool by folate,0.3924118011503742,1.249758873689438,0.20222634508348794,0.46095863935059916,1.0,6/7,47.40%,ATIC;SHMT2;ALDH1L1;MTHFD1;SHMT1;GART
107,prerank,Small cell lung cancer,0.3303994955081162,1.2468634229725113,0.1978021978021978,0.4573690128966511,1.0,4/10,9.00%,FN1;LAMB1;LAMC1;LAMA5
108,prerank,Lipid and atherosclerosis,0.1898901494302087,1.2460904603078524,0.21837088388214904,0.45067714948368215,1.0,8/33,7.13%,APOB;APOA1;HSPA1A;HSP90AB1;HSP90AA1;HSPA5;RAP1B;HSP90B1
109,prerank,Arachidonic acid metabolism,0.38602109071766644,1.2433733108267284,0.2176360225140713,0.4468750635769943,1.0,5/7,33.72%,AKR1C3;PLA2G2A;PTGES3;GPX3;CBR1
110,prerank,GABAergic synapse,-0.33303316885960477,-1.2322563913928417,0.20044543429844097,0.5122334046227451,1.0,6/9,32.44%,GNAI2;GNB4;GPHN;SRC;GNB2;PRKACA
111,prerank,Human T-cell leukemia virus 1 infection,-0.20773507350764558,-1.2237560726452215,0.20642201834862386,0.518749407773798,1.0,14/22,41.73%,B2M;HLA-G;RANBP1;STAT5B;MAPK1;SLC25A31;PPP3CA;NRAS;PRKACA;HLA-C;MAP2K1;ICAM1;CALR;BUB3
112,prerank,Lysine degradation,0.2773092055835617,1.223378798391854,0.20255474452554745,0.47138044333071194,1.0,10/14,44.89%,PLOD1;PLOD2;PLOD3;ALDH9A1;ALDH7A1;ECHS1;ALDH2;ACAT1;DLST;ACAT2
113,prerank,Protein processing in endoplasmic reticulum,0.15293095627069475,1.2215367315213326,0.19547657512116318,0.46689935990251125,1.0,42/49,71.60%,HSPA1A;MAN1A1;VCP;HSP90AB1;HSP90AA1;PDIA6;HSPA5;HSP90B1;HYOU1;GANAB;PDIA3;HSPA8;SEC23A;P4HB;RRBP1;LMAN2;DNAJB11;SIL1;CAPN2;SEC24C;SEC31A;PDIA4;EIF2S1;SAR1A;UGGT1;FBXO2;DNAJC3;SEC24A;OS9;NSFL1C;CALR;ERO1A;DNAJA2;RBX1;MOGS;MBTPS1;DNAJB1;HSPH1;SAR1B;BAG2;SEC13;UBE2D2
114,prerank,Melanoma,-0.3717013659544392,-1.2197075928489105,0.21908893709327548,0.5170307334941482,1.0,6/7,48.16%,PDGFC;MAPK1;NRAS;PDGFA;MAP2K1;MAPK3
115,prerank,Other glycan degradation,0.3389817975639107,1.214860784029489,0.21001926782273603,0.4704677232315424,1.0,8/9,55.46%,HEXB;MAN2B1;GLB1;FUCA1;FUCA2;NEU1;GBA;MANBA
116,prerank,Circadian entrainment,-0.33316431674791125,-1.2087375099919568,0.21413721413721415,0.5289718720399079,1.0,7/8,53.83%,GNAI2;GNB4;MAPK1;GNB2;PRKACA;MAPK3;GNB1
117,prerank,Thyroid hormone signaling pathway,-0.2337730207802903,-1.2045898354774516,0.2423580786026201,0.526694725391109,1.0,15/18,59.15%,NOTCH4;PFKP;ITGB3;SRC;STAT1;MAPK1;CTNNB1;NRAS;BMP4;PRKACA;MAP2K1;MAPK3;ATP1A1;PFKL;HDAC1
118,prerank,Breast cancer,-0.3708073128680842,-1.2001518878355761,0.22784810126582278,0.5253233247239035,1.0,6/7,48.16%,NOTCH4;MAPK1;CTNNB1;NRAS;MAP2K1;MAPK3
119,prerank,Ferroptosis,-0.2921574456473962,-1.1965957694588838,0.24761904761904763,0.5227755194218608,1.0,10/12,53.36%,GSS;ACSL4;ACSL1;CP;GCLC;SLC3A2;TFRC;FTL;PCBP2;PCBP1
120,prerank,Pathogenic Escherichia coli infection,0.15611857811676372,1.187108427957284,0.23310810810810811,0.5097777665122587,1.0,23/46,36.41%,GAPDH;ACTB;F2;TUBA1C;TUBB4B;TUBA4A;TUBB1;NCL;TUBB;ARF1;MYH9;RPS3;EZR;ARPC4;RAC1;TUBB3;ACTR3;TUBA8;ARPC2;ROCK2;MYH10;ARPC5;SEC24C
121,prerank,Renin-angiotensin system,-0.37346934881855687,-1.1852896122145469,0.2539325842696629,0.535728443665269,1.0,6/7,47.75%,ATP6AP2;THOP1;ACE;CTSA;PREP;PRCP
122,prerank,Proteoglycans in cancer,0.14714382700883996,1.1708591523968195,0.262350936967632,0.5316455104305648,1.0,12/49,11.86%,VTN;FN1;ACTB;GPC3;LUM;SDC1;TGFB1;FLNA;THBS1;SDC4;HSPG2;IGF2
123,prerank,Progesterone-mediated oocyte maturation,-0.3044924997310818,-1.169999413340617,0.27293577981651373,0.5551531983475335,1.0,8/10,48.16%,GNAI2;MAPK14;CDK1;MAPK1;RPS6KA3;PRKACA;MAP2K1;MAPK3
124,prerank,Homologous recombination,-0.41793669402110195,-1.159409594900912,0.27370689655172414,0.5652595923598633,1.0,5/5,58.39%,BABAM2;RAD50;RPA2;RPA1;SSBP1
125,prerank,Measles,-0.26655224307332887,-1.1557384847399064,0.2686230248306998,0.563610991678827,1.0,8/13,33.26%,RAB9A;STAT5B;STAT1;STAT3;CSNK2B;CYCS;EIF3H;CSNK2A1
126,prerank,B cell receptor signaling pathway,-0.3264831853254363,-1.148002525866867,0.2606924643584521,0.5699994120256784,1.0,7/8,54.53%,MAPK1;PPP3CA;IFITM1;NRAS;MAP2K1;MAPK3;CD81
127,prerank,Other types of O-glycan biosynthesis,-0.3801782543202187,-1.1432871841458834,0.28440366972477066,0.5699161197128677,1.0,4/6,27.64%,GALNT2;COLGALT1;ST6GAL1;GALNT7
128,prerank,IL-17 signaling pathway,0.2991127473142009,1.1406641662853358,0.28028933092224234,0.5764675023468994,1.0,4/10,11.98%,HSP90AB1;HSP90AA1;HSP90B1;SRSF1
129,prerank,Starch and sucrose metabolism,0.28941176470588237,1.1404776139053414,0.2884955752212389,0.5677999371859296,1.0,11/11,71.24%,AMY1A;PYGB;UGP2;PYGL;PGM1;GPI;AGL;GAA;GYS1;HK1;HK2
130,prerank,Peroxisome,-0.29116767685229017,-1.1212806774200228,0.3108108108108108,0.603988603988604,1.0,4/10,8.94%,HMGCL;ACAA1;ACSL4;ACSL1
131,prerank,Pantothenate and CoA biosynthesis,-0.40307229302670844,-1.1178864168413531,0.29175946547884185,0.6019701345203496,1.0,3/5,18.35%,VNN1;ALDH1B1;DPYS
132,prerank,VEGF signaling pathway,-0.28182814247775206,-1.1116906479566673,0.30337078651685395,0.6048514117619808,1.0,10/11,62.54%,SRC;MAPK14;VEGFA;MAPK1;PPP3CA;NRAS;MAP2K1;MAPK3;CDC42;HSPB1
133,prerank,Natural killer cell mediated cytotoxicity,-0.26118178327019526,-1.109231432609628,0.3049792531120332,0.6011656590924884,1.0,9/12,48.16%,HLA-G;MAPK1;PPP3CA;NRAS;PTPN11;HLA-C;MAP2K1;ICAM1;MAPK3
134,prerank,Ras signaling pathway,-0.184532387096841,-1.104096927542713,0.3273942093541203,0.6023213843550499,1.0,14/24,38.87%,RRAS;PDGFC;GNB4;VEGFA;MAPK1;PLA1A;GNB2;ARF6;NRAS;PRKACA;PTPN11;PDGFA;MAP2K1;RAB5B
135,prerank,Platelet activation,0.17298115431577663,1.0986937714217024,0.32717190388170053,0.6391067764859801,1.0,7/30,8.12%,FGB;FGA;ACTB;F2;TLN1;RAP1B;FGG
136,prerank,Cushing syndrome,-0.2588701335440691,-1.096357127017607,0.3295964125560538,0.6091837877068229,1.0,9/12,48.16%,GNAI2;WDR5;MAPK1;FH;CTNNB1;PRKACA;MAP2K1;SCARB1;MAPK3
137,prerank,Leishmaniasis,0.30043717102776735,1.0942239978611508,0.3370165745856354,0.6380547844115683,1.0,3/9,6.20%,C3;EEF1A1;TGFB1
138,prerank,RNA transport,-0.13608502561656857,-1.0930721387102589,0.32926829268292684,0.6069135199606298,1.0,39/45,72.71%,SUMO2;EIF2B4;UPF1;NUP93;RPP30;EIF2S2;UBE2I;PABPC4;EIF3J;FUS;EIF3G;NCBP1;STRAP;EIF4B;DDX19A;RANGAP1;EIF3H;EIF5B;SEC13;CYFIP2;ALYREF;XPOT;EIF3I;EIF4E;PABPC1;EIF3D;EIF2S3;MAGOH;XPO1;TPR;EIF2S1;EIF4A2;EIF3E;EIF3B;EIF3F;PRMT5;EIF4A3;EIF3A;EIF3C
139,prerank,"Alanine, aspartate and glutamate metabolism",0.2596496233641211,1.0852710779367158,0.33454545454545453,0.6457315279035822,1.0,8/12,42.14%,GLUD1;ASS1;GFPT1;ALDH5A1;ASL;ABAT;ADSL;NIT2
140,prerank,Glucagon signaling pathway,0.2074389449530858,1.07839636245012,0.35283018867924526,0.6501512085313446,1.0,9/20,26.18%,PKM;LDHA;PGAM1;PYGB;SLC2A1;LDHB;PYGL;PCK2;CALM1
141,prerank,Melanogenesis,-0.2893011242410751,-1.0754266460230615,0.3381742738589212,0.633126325199496,1.0,7/9,48.16%,GNAI2;MAPK1;CTNNB1;NRAS;PRKACA;MAP2K1;MAPK3
142,prerank,Synthesis and degradation of ketone bodies,-0.388042203985932,-1.0748368534268928,0.362,0.6259882333866074,1.0,5/5,61.37%,HMGCL;BDH2;HMGCS1;ACAT2;ACAT1
143,prerank,Chronic myeloid leukemia,-0.2907652736613799,-1.0718923549395298,0.35095137420718814,0.6238468212954734,1.0,8/9,59.15%,CTBP1;STAT5B;MAPK1;NRAS;PTPN11;MAP2K1;MAPK3;HDAC1
144,prerank,Fc epsilon RI signaling pathway,-0.3459390496767817,-1.0682485788040248,0.3463203463203463,0.622441244392464,1.0,5/6,48.16%,MAPK14;MAPK1;NRAS;MAP2K1;MAPK3
145,prerank,Glycerophospholipid metabolism,-0.2750553183039013,-1.0648986539053973,0.3744075829383886,0.6203852924459554,1.0,7/10,41.50%,GPD1L;LYPLA2;PLD3;PCYT1A;PLA1A;PCYT2;LYPLA1
146,prerank,Glioma,-0.3476490066196345,-1.058413122441051,0.3465553235908142,0.6251439234613053,1.0,5/6,48.16%,MAPK1;NRAS;PDGFA;MAP2K1;MAPK3
147,prerank,Pentose phosphate pathway,0.21972932418966817,1.0552836081340888,0.36042402826855124,0.6862195593351372,1.0,12/16,54.24%,TKT;ALDOC;ALDOA;G6PD;PGD;PGM1;RGN;GPI;PFKL;TALDO1;FBP1;PRPS1
148,prerank,TNF signaling pathway,-0.3082795067527892,-1.0549586810903395,0.39622641509433965,0.623818488986172,1.0,8/8,69.37%,MAPK14;MAPK1;MAP2K1;ICAM1;VCAM1;MAPK3;DNM1L;CCL20
149,prerank,beta-Alanine metabolism,-0.25705882352941173,-1.053989898586739,0.3741339491916859,0.6179706795485176,1.0,11/11,74.52%,ALDH1B1;DPYS;AOC3;HADHA;DPYD;ABAT;ALDH2;ECHS1;ALDH7A1;CNDP2;ALDH9A1
150,prerank,Bile secretion,0.32453051643192476,1.0535406493933326,0.3701067615658363,0.6799450549450549,1.0,7/7,67.68%,SLC2A1;EPHX1;LDLR;ATP1A1;SULT2A1;SCARB1;PRKACA
151,prerank,Osteoclast differentiation,-0.2889602664954801,-1.050213001359593,0.38631346578366443,0.6172334589199551,1.0,5/9,25.48%,ITGB3;MAPK14;STAT1;MAPK1;PPP3CA
152,prerank,Bladder cancer,-0.28623430009597456,-1.048673640930227,0.4053452115812918,0.6125314265190844,1.0,7/9,48.16%,MMP2;SRC;VEGFA;MAPK1;NRAS;MAP2K1;MAPK3
153,prerank,Tyrosine metabolism,0.304193177909859,1.0453422275133146,0.38632162661737524,0.6859010654572973,1.0,4/8,21.33%,MIF;HGD;ADH5;TYRP1
154,prerank,Hepatitis C,0.1889810426540282,1.0450803042446632,0.3862433862433862,0.6769907228449942,1.0,23/23,81.36%,PPP2CA;YWHAZ;YWHAQ;YWHAE;YWHAG;PPP2R1A;LDLR;YWHAB;EIF3E;EIF2S1;CD81;YWHAH;MAPK3;PSME3;SCARB1;MAP2K1;PPP2R2A;NRAS;CTNNB1;CYCS;MAPK1;STAT3;STAT1
155,prerank,Cardiac muscle contraction,-0.3174882629107981,-1.0289381749396371,0.4489795918367347,0.643205409465572,1.0,7/7,68.44%,TPM3;ASPH;TPM4;COX7A2;ATP1A1;CACNA2D1;TPM1
156,prerank,Endometrial cancer,-0.2894891368173811,-1.0263262747838429,0.38074398249452956,0.640293974583788,1.0,8/8,71.24%,CTNNA1;MAPK1;CTNNB1;NRAS;MAP2K1;MAPK3;ILK;CDH1
157,prerank,Rap1 signaling pathway,0.17479802745671244,1.0139363526896372,0.43566176470588236,0.7313265484429523,1.0,6/26,7.60%,ACTB;PARD3;PFN1;TLN1;RAP1B;THBS1
158,prerank,Ribosome biogenesis in eukaryotes,-0.2316072942240628,-1.011647534452887,0.4608294930875576,0.659551229531377,1.0,10/13,53.01%,EMG1;RPP30;XRN2;CSNK2B;CSNK2A1;SNU13;TCOF1;NOP58;NOP56;XPO1
159,prerank,HIF-1 signaling pathway,0.15961161959632886,1.0113812664498532,0.4235500878734622,0.7267209227008222,1.0,29/30,81.18%,GAPDH;PGK1;ENO1;LDHA;TF;SLC2A1;ALDOC;LDHB;ALDOA;SERPINE1;TIMP1;ELOB;PFKL;ENO3;MAPK3;TFRC;RPS6;EIF4E;ENO2;RBX1;MAP2K1;ALDOB;HK1;PDHA1;HK2;CUL2;MAPK1;STAT3;VEGFA
160,prerank,Toll-like receptor signaling pathway,-0.2795313858694291,-1.0089081885364197,0.43070362473347545,0.6569469504008332,1.0,4/8,21.04%,MAPK14;STAT1;TOLLIP;MAPK1
161,prerank,Adherens junction,0.2004276800372215,1.0042407620757714,0.42010771992818674,0.7318631619636644,1.0,9/19,29.16%,ACTB;PARD3;PTPRF;ACTN1;RAC1;ACTN4;CDH1;IQGAP1;ACP1
162,prerank,Fatty acid degradation,-0.1959858323494687,-0.9979177935156861,0.45584725536992843,0.6708290298229322,1.0,17/17,80.65%,ACAA1;ACSL4;ACSL1;ALDH1B1;ACAA2;HADHB;HADHA;HADH;ACAT2;ACADSB;ACAT1;ALDH2;ECHS1;ALDH7A1;ACADVL;ALDH9A1;ADH5
163,prerank,Galactose metabolism,0.2246657311611815,0.9880520491899026,0.45663716814159294,0.7548483815840336,1.0,11/14,57.10%,GALK1;UGP2;B4GALT1;GLB1;PGM1;GALM;AKR1B1;GLA;PFKL;GAA;AKR1B10
164,prerank,MicroRNAs in cancer,-0.16230826046981706,-0.9843992353103461,0.4575892857142857,0.6889894511160611,1.0,10/26,21.04%,MARCKS;NOTCH4;CD44;VIM;UBE2I;ITGB3;VEGFA;STAT3;IGF2BP1;MAPK1
165,prerank,Toxoplasmosis,0.1908468149174758,0.969662112554141,0.47424511545293074,0.7830988107370017,1.0,7/19,19.81%,HSPA1A;LAMB1;TGFB1;LAMC1;LAMA5;HSPA8;LAMB2
166,prerank,Synaptic vesicle cycle,-0.22252717397309155,-0.9629368980735825,0.474835886214442,0.7237137022367375,1.0,11/12,69.26%,NAPA;AP2A2;CLTB;ATP6V1B2;ATP6V1A;CLTA;DNM2;AP2A1;AP2B1;NSF;AP2M1
167,prerank,Wnt signaling pathway,-0.18882034354753535,-0.9610816865992415,0.4966292134831461,0.7189967630868194,1.0,10/17,38.69%,CTBP1;SKP1;CUL1;CSNK2B;PPP3CA;CTNNB1;PRKACA;CSNK2A1;CACYBP;RBX1
168,prerank,Tuberculosis,0.16911909608124837,0.9609736702850556,0.4824561403508772,0.7910335702179536,1.0,10/24,26.59%,C3;TGFB1;CTSD;HSPD1;HSPA9;LBP;CD74;CORO1A;CALM1;MRC2
169,prerank,Rheumatoid arthritis,-0.29263998390323914,-0.9597872392613773,0.49324324324324326,0.7138130564694721,1.0,5/7,40.97%,ATP6AP1;VEGFA;ATP6V1B2;ICAM1;ATP6V1A
170,prerank,Spliceosome,-0.10727963185647811,-0.957383732742413,0.5301837270341208,0.7106306360830358,1.0,32/56,45.53%,SRSF10;DDX42;SNRNP70;PRPF8;DDX23;CTNNBL1;FUS;NCBP1;HNRNPM;HNRNPA3;PRPF40A;SNRNP40;LSM6;CDC5L;SF3B2;SF3A3;EFTUD2;TRA2B;SNRPB;TCERG1;DHX15;SF3A1;RBM25;SNRPF;ALYREF;SNRPE;U2AF2;SNRPA;SNU13;SNRPA1;RBMX;LSM3
171,prerank,Central carbon metabolism in cancer,0.18716955270954444,0.9532002261517329,0.4896810506566604,0.7975013822765238,1.0,7/19,19.93%,PKM;LDHA;PGAM1;SLC2A1;LDHB;G6PD;IDH1
172,prerank,Phospholipase D signaling pathway,-0.21842095971167008,-0.9509445245986363,0.5053763440860215,0.7159110229945724,1.0,8/13,38.22%,RRAS;PDGFC;MAPK1;ARF6;NRAS;PTPN11;PDGFA;MAP2K1
173,prerank,Hepatocellular carcinoma,0.19168224528337063,0.9483268754713933,0.49822695035460995,0.7970235794356397,1.0,16/18,70.54%,ACTB;TGFB1;GSTA5;IGF2;GSTO1;GSTP1;GSTM3;GSTA1;GSTM2;NQO1;MAPK3;MAP2K1;ACTL6A;NRAS;CTNNB1;GSTM1
174,prerank,Aldosterone synthesis and secretion,0.29107981220657275,0.9386918069908404,0.5128676470588235,0.8071017480565219,1.0,7/7,71.01%,AGT;CALM1;LDLR;ATP1A1;SCARB1;PRKACA;PDE2A
175,prerank,Oocyte meiosis,-0.15348712433856074,-0.9383350436172447,0.5273972602739726,0.7307714251231581,1.0,17/25,51.72%,PPP2R5D;SKP1;PPP1CC;SMC1A;MAPK14;CDK1;MAPK1;CUL1;PPP3CA;RPS6KA3;PRKACA;MAP2K1;RBX1;PPP1CB;PPP1CA;MAPK3;YWHAH
176,prerank,Fluid shear stress and atherosclerosis,0.14660712247943247,0.9294065660490639,0.5298013245033113,0.8159158833567461,1.0,7/31,9.59%,ACTB;HSP90AB1;HSP90AA1;SDC1;GSTA5;HSP90B1;SDC4
177,prerank,Herpes simplex virus 1 infection,-0.14424563809275998,-0.928882014580275,0.497737556561086,0.7408120381951684,1.0,10/29,18.76%,B2M;SRPK1;EIF2B4;HLA-G;JAK2;ITGB3;PPP1CC;SRC;HCFC1;STAT1
178,prerank,Non-alcoholic fatty liver disease,-0.19256617944099944,-0.9238239141165286,0.4964871194379391,0.7423901822946328,1.0,12/15,60.14%,PRKAA1;MAPK14;PRKAG1;CYCS;SDHB;COX7A2;NDUFV1;SDHA;EIF2S1;CDC42;NDUFS1;PKLR
179,prerank,Endocrine and other factor-regulated calcium reabsorption,0.24258823079737155,0.9217998580055117,0.5307262569832403,0.8217407705813591,1.0,7/10,46.81%,CLTC;AP2M1;AP2B1;AP2A1;DNM2;CLTA;ATP1A1
180,prerank,Amino sugar and nucleotide sugar metabolism,0.1647895672791939,0.9212643254288388,0.5506535947712419,0.8131592026064388,1.0,24/24,83.75%,UGDH;GALK1;UGP2;NANS;HEXB;CHIA;CYB5R3;PGM1;GFPT1;UXS1;GPI;GMDS;PMM2;HK1;PGM3;HEXA;HK2;GMPPB;NAGK;GNPNAT1;UAP1;GFUS;GNE;CMAS
181,prerank,Pyruvate metabolism,0.16706161137440756,0.919908304550677,0.5316901408450704,0.8063450737852156,1.0,23/23,83.52%,PKM;LDHA;AKR1A1;LDHB;MDH2;ADH5;PCK2;ALDH9A1;ALDH7A1;ALDH2;ACAT1;PKLR;ACAT2;GLO1;ME2;ME1;MDH1;PDHA1;ACSS2;FH;PCK1;GRHPR;ALDH1B1
182,prerank,Non-small cell lung cancer,-0.26036637356491515,-0.9182531812243322,0.5298165137614679,0.7453375763480293,1.0,6/8,48.16%,STAT5B;STAT3;MAPK1;NRAS;MAP2K1;MAPK3
183,prerank,Glycosaminoglycan biosynthesis,-0.2314217095577754,-0.9154090138722278,0.5875831485587583,0.7430759544580682,1.0,6/10,35.48%,ST3GAL1;NDST1;B3GAT3;XYLT2;HS6ST1;GLCE
184,prerank,Gastric cancer,-0.2578150889408053,-0.9099213288921475,0.5357142857142857,0.7463649155722326,1.0,6/8,48.16%,CTNNA1;MAPK1;CTNNB1;NRAS;MAP2K1;MAPK3
185,prerank,NF-kappa B signaling pathway,-0.2627064069363583,-0.9057416428495141,0.5498938428874734,0.7468806136398506,1.0,6/8,47.98%,UBE2I;TRIM25;CSNK2B;CSNK2A1;ICAM1;VCAM1
186,prerank,cAMP signaling pathway,-0.18996467972152759,-0.903651668629697,0.5773420479302832,0.7432896513479966,1.0,11/15,53.30%,RRAS;PPP1R12A;GNAI2;PPP1CC;MAPK1;PRKACA;MAP2K1;PPP1CB;PPP1CA;MAPK3;ATP1A1
187,prerank,DNA replication,0.32582606177219386,0.903065948123142,0.592156862745098,0.8311413957084169,1.0,4/5,48.33%,FEN1;PCNA;SSBP1;RPA1
188,prerank,Glyoxylate and dicarboxylate metabolism,0.20920734743509173,0.9012282408975665,0.5636363636363636,0.8251869426709143,1.0,9/14,44.89%,SHMT2;CS;MDH2;ACO1;ACO2;ACAT1;SHMT1;CAT;ACAT2
189,prerank,Salmonella infection,0.09820400159990571,0.9002638030877468,0.555008210180624,0.8176975348771831,1.0,32/69,38.63%,GAPDH;ACTB;PFN1;TUBA1C;HSP90AB1;HSP90AA1;TUBB4B;TUBA4A;FLNA;HSP90B1;TUBB1;TUBB;ARF1;RPS3;ARPC4;DYNC1H1;FLNB;AHNAK2;RAC1;TUBB3;ACTR3;CSE1L;TUBA8;ARPC2;ROCK2;ACTR1A;RAB7A;RAB5C;ARPC5;KIF5B;PFN2;DNM2
190,prerank,Cell adhesion molecules,0.1779414990496383,0.8936985417654658,0.5762411347517731,0.8212822973988352,1.0,17/19,72.53%,SDC1;PTPRF;CNTN1;SDC4;HLA-A;CDH1;VCAN;NEO1;ICOSLG;GLG1;VCAM1;CDH5;ICAM1;HLA-C;ITGB1;PTPRM;NCAM1
191,prerank,p53 signaling pathway,-0.3244446256948066,-0.8926480576721714,0.584051724137931,0.7554983123891483,1.0,3/5,25.77%,RRM2B;CDK1;CYCS
192,prerank,Cytokine-cytokine receptor interaction,0.30263929618768337,0.8910834137822102,0.5944444444444444,0.8172013915732509,1.0,6/6,69.84%,GDF15;TGFB1;CCL20;INHBE;IL1RAP;BMP4
193,prerank,Mismatch repair,0.3250148225379331,0.8867986698824368,0.5789473684210527,0.8161730036488444,1.0,4/5,48.33%,PCNA;MSH3;SSBP1;RPA1
194,prerank,Prostate cancer,0.22015532794618442,0.8859323323797519,0.618018018018018,0.8088897665585453,1.0,3/11,7.13%,HSP90AB1;HSP90AA1;HSP90B1
195,prerank,Renal cell carcinoma,0.18985849056603762,0.8811552924071979,0.5985130111524164,0.8091979749865954,1.0,15/15,81.18%,TGFB1;RAP1B;SLC2A1;RAC1;CDC42;ELOB;MAPK3;RBX1;MAP2K1;PTPN11;NRAS;CUL2;FH;MAPK1;VEGFA
196,prerank,Diabetic cardiomyopathy,0.13626434211891292,0.8810461390486897,0.589041095890411,0.8008022929705813,1.0,29/32,77.73%,GAPDH;TGFB1;ATP5F1B;CTSD;SLC2A1;AGT;G6PD;RAC1;COL1A1;NDUFA9;PARP1;ATP5F1A;GFPT1;NDUFS1;SDHA;COL1A2;GSR;PPP1CA;PPP1CB;NDUFV1;GYS1;COX7A2;SDHB;COL3A1;PDHA1;PTPA;SLC25A31;ACE;ATP5PO
197,prerank,Nucleotide excision repair,-0.24662360540223136,-0.8770511854647671,0.5983606557377049,0.7770073977860094,1.0,8/8,75.51%,CUL4A;RAD23B;RPA2;CUL4B;RBX1;RPA1;DDB1;PCNA
198,prerank,Bacterial invasion of epithelial cells,0.14236075830080827,0.8745025431372518,0.6215277777777778,0.8043568042642362,1.0,18/29,49.44%,FN1;ACTB;CLTC;ARPC4;SEPTIN9;RAC1;ACTR3;CDH1;ILK;ARPC2;SEPTIN11;ARPC5;SEPTIN2;DNM2;CDC42;CLTA;VCL;ARPC3
199,prerank,Epstein-Barr virus infection,0.12955266381547592,0.8710047283458564,0.6176961602671118,0.8022927135678392,1.0,19/35,43.07%,PSMD14;PDIA3;PSMC5;PSMC3;PSMC4;RAC1;PSMD13;PSMC1;HLA-A;PSMC2;PSMC6;PSMD12;PSMD11;PSMD8;PSMD3;HDAC1;PSMD6;PSMD2;PSMD1
200,prerank,MAPK signaling pathway,-0.14019411414983265,-0.8709499324275665,0.6085972850678733,0.7812022064054583,1.0,14/26,38.22%,RRAS;MAP4K4;PDGFC;MAPK14;VEGFA;ARRB1;MAPK1;PPP3CA;RPS6KA3;NRAS;PRKACA;IL1RAP;PDGFA;MAP2K1
201,prerank,Lysosome,-0.10658445027313948,-0.8649915395193922,0.640625,0.7846919851636833,1.0,33/44,63.59%,CLN5;AP1G2;AP3M1;SMPD1;LIPA;SCARB2;ATP6AP1;GUSB;AP1S1;PPT1;AP1S2;CD63;GNS;CLTB;HEXA;CTSA;TPP1;NAGA;MANBA;GAA;GBA;CTSC;NEU1;FUCA2;CTSV;AP3B1;CLTA;HYAL1;AP1G1;AP1M1;FUCA1;CTSZ;GLA
202,prerank,Amphetamine addiction,-0.26243291556585385,-0.8575647514810419,0.6400862068965517,0.7904552559783926,1.0,6/7,59.15%,PPP1CC;PPP3CA;PRKACA;PPP1CB;PPP1CA;HDAC1
203,prerank,Shigellosis,0.10746383762558563,0.8545546087397695,0.6182432432432432,0.8239153738557975,1.0,24/51,38.16%,C3;ACTB;PFN1;H3-3A;TLN1;RPS27A;ARF1;ACTN1;ARPC4;SEPTIN9;RAC1;ACTR3;ACTN4;ILK;CAPN2;ARPC2;ROCK2;SEPTIN11;DIAPH1;UBE2V1;ARPC5;SEPTIN7;SEPTIN2;PFN2
204,prerank,Oxidative phosphorylation,-0.18306327857070237,-0.8427162963258821,0.6850574712643678,0.809410684918815,1.0,13/14,74.34%,ATP6AP1;ATP5PO;ATP6V1B2;SDHB;COX7A2;ATP6V1A;NDUFV1;SDHA;NDUFS1;ATP5F1A;PPA1;PPA2;NDUFA9
205,prerank,NOD-like receptor signaling pathway,0.21871971494425985,0.8377622112760169,0.6320582877959927,0.8466143511908049,1.0,3/10,9.88%,HSP90AB1;HSP90AA1;CTSB
206,prerank,Arrhythmogenic right ventricular cardiomyopathy,-0.20502370769945005,-0.8339862007606638,0.6559633027522935,0.8175323325804418,1.0,6/11,32.73%,CTNNA1;ITGB3;ITGA2;CTNNB1;DSP;ITGB1
207,prerank,Histidine metabolism,-0.2564553990610329,-0.8320651676371221,0.6431818181818182,0.8135708239366775,1.0,7/7,74.52%,UROC1;ALDH1B1;FTCD;ALDH2;ALDH7A1;CNDP2;ALDH9A1
208,prerank,Pancreatic cancer,-0.22287457480619577,-0.8306519120559321,0.6711409395973155,0.8087579449368069,1.0,4/9,21.04%,STAT1;VEGFA;STAT3;MAPK1
209,prerank,Dilated cardiomyopathy,0.17966797224746914,0.8281896153874583,0.6725043782837128,0.8548775345257758,1.0,14/15,75.86%,ACTB;TGFB1;LMNA;AGT;TPM1;CACNA2D1;TTN;LAMA2;DAG1;ITGB1;PRKACA;TPM4;ITGA2;TPM3
210,prerank,Vascular smooth muscle contraction,0.16618040802325001,0.8280150492767282,0.6389891696750902,0.8465983764978741,1.0,15/18,67.68%,MYH9;AGT;PLA2G2A;MYL6;CALM1;ROCK2;MYH10;MYH14;MYLK2;MAPK3;PPP1CA;PPP1CB;MAP2K1;MYLK;PRKACA
211,prerank,Type I diabetes mellitus,0.27640434930291835,0.8201008586111749,0.6833013435700576,0.8518219429210026,1.0,4/6,40.44%,HLA-A;HSPD1;PRF1;CPE
212,prerank,Autophagy,-0.17375491094201073,-0.8163256045827596,0.671264367816092,0.8257610163097969,1.0,10/15,48.16%,RRAS;PRKAA1;MAPK1;HMGB1;NRAS;PRKACA;MAP2K1;SH3GLB1;RAB1A;MAPK3
213,prerank,Adrenergic signaling in cardiomyocytes,-0.15244295246222475,-0.8107862017789289,0.6696035242290749,0.8280943780620016,1.0,17/19,73.93%,GNAI2;PPP2R5D;PPP1CC;MAPK14;MAPK1;TPM3;TPM4;PRKACA;PPP2R2A;PPP1CB;PPP1CA;MAPK3;ATP1A1;CACNA2D1;TPM1;PPP2R1A;CALM1
214,prerank,Olfactory transduction,-0.26217008797653957,-0.802264266110305,0.7178947368421053,0.8347770353546989,1.0,6/6,73.93%,ARRB1;PDE2A;PRKACA;GNB1;OR1D4;CALM1
215,prerank,Vasopressin-regulated water reabsorption,-0.17442545668827342,-0.7977443509301134,0.7077625570776256,0.8347445414253474,1.0,14/14,82.76%,ARHGDIA;DYNC1LI2;DCTN4;DYNC1LI1;DCTN2;PRKACA;DYNC1I2;RAB5B;RAB5A;DCTN1;RAB5C;NSF;RAB11B;DYNC1H1
216,prerank,AGE-RAGE signaling pathway in diabetic complications,-0.14162584493242,-0.795656324431227,0.7383177570093458,0.8307994220525761,1.0,8/22,21.04%,MMP2;JAK2;STAT5B;MAPK14;STAT1;VEGFA;STAT3;MAPK1
217,prerank,Cell cycle,0.16760932710996812,0.7949948622704849,0.7300509337860781,0.8854737488346711,1.0,9/16,40.97%,TGFB1;YWHAZ;YWHAQ;YWHAE;PCNA;YWHAG;PRKDC;YWHAB;HDAC1
218,prerank,Fc gamma R-mediated phagocytosis,0.1533123138990527,0.787402052244054,0.7254545454545455,0.889374054739718,1.0,16/20,65.81%,GSN;ARPC4;RAC1;ACTR3;CFL1;ARPC2;ARPC5;DNM2;VASP;CDC42;ARPC3;MAPK3;ARPC1B;ARPC5L;MAP2K1;ACTR2
219,prerank,Folate biosynthesis,-0.21618301108455884,-0.7870031185832009,0.74235807860262,0.8376556869886035,1.0,8/9,66.74%,PAH;SPR;GPHN;AKR1B10;GGH;QDPR;CBR1;AKR1B1
220,prerank,Sphingolipid signaling pathway,-0.1643354420330469,-0.7867766113375045,0.7392290249433107,0.8310106422446233,1.0,10/15,49.04%,SMPD1;GNAI2;PPP2R5D;MAPK14;MAPK1;NRAS;PPP2R2A;MAP2K1;MAPK3;KNG1
221,prerank,TGF-beta signaling pathway,0.17491458947004918,0.785978991044801,0.7357142857142858,0.8833228643216081,1.0,4/15,10.64%,TGFB1;THBS1;FMOD;PPP2CA
222,prerank,Pathways in cancer,-0.07879626099727202,-0.7801705256054624,0.7965616045845272,0.8341701074843112,1.0,28/67,32.73%,CTBP1;NOTCH4;GNAI2;MMP2;GNB4;JAK2;CTNNA1;SKP1;STAT5B;TFG;STAT1;VEGFA;STAT3;MAPK1;CCDC6;FH;TPM3;CUL1;CYCS;GNB2;ITGA2;CUL2;GSTM1;CTNNB1;NRAS;BMP4;PRKACA;ITGB1
223,prerank,Purine metabolism,0.12463070458094991,0.7792105681194297,0.7383333333333333,0.8857280910044729,1.0,29/30,84.63%,PKM;ATIC;PAICS;APRT;ADK;PGM1;NME1;GMPR2;GMPS;PKLR;ADSL;IMPDH2;AMPD2;GART;PFAS;PRPS1;AK4;RRM1;NT5C2;PPAT;ADSS1;PDE2A;PAPSS1;PNP;AK3;PDE5A;ITPA;ADSS2;RRM2B
224,prerank,Gap junction,0.15512752965672646,0.7773617715914574,0.7304189435336976,0.8803095667014316,1.0,5/19,12.57%,TUBA1C;TUBB4B;TUBA4A;TUBB1;TUBB
225,prerank,Steroid hormone biosynthesis,-0.2729626481796447,-0.7720449676493827,0.7670682730923695,0.8397017522525653,1.0,3/5,31.50%,COMT;DHRS11;SULT1E1
226,prerank,Colorectal cancer,0.21034077555816688,0.7714809537556562,0.7627737226277372,0.8808284773977725,1.0,9/9,79.08%,TGFB1;RAC1;MSH3;MAPK3;MAP2K1;NRAS;CTNNB1;CYCS;MAPK1
227,prerank,Endocytosis,0.09097024480057099,0.770098671149633,0.7513043478260869,0.8751610617188507,1.0,29/63,38.63%,PARD3;HSPA1A;IGF2R;CLTC;HSPA8;ARF1;ARPC4;EHD3;RAB11B;HLA-A;VPS35;ACTR3;CAPZA1;ARF4;ARF5;CAPZB;AP2M1;ARPC2;SNX2;LDLR;PDCD6IP;AP2B1;RAB7A;RAB5C;AP2A1;ARPC5;EHD1;KIF5B;DNM2
228,prerank,Protein digestion and absorption,0.13612669583356357,0.7581822265104899,0.7818853974121996,0.886042775628318,1.0,18/22,69.32%,COL6A1;CPA1;COL6A3;COL18A1;COL1A1;CPB2;COL2A1;COL6A2;COL12A1;COL15A1;ATP1A1;COL1A2;PRCP;SLC3A2;COL5A1;COL3A1;DPP4;COL9A1
229,prerank,Renin secretion,-0.23145775766119137,-0.7580775516730994,0.7638297872340426,0.8538088543631781,1.0,4/7,32.44%,GNAI2;ACE;PPP3CA;PRKACA
230,prerank,Fructose and mannose metabolism,0.15595166295249913,0.7555814451167744,0.7684210526315789,0.8818304810767122,1.0,15/17,73.29%,ALDOC;TPI1;ALDOA;SORD;AKR1B1;TKFC;PFKL;GMDS;FBP1;PMM2;AKR1B10;ALDOB;HK1;HK2;GMPPB
231,prerank,Ovarian steroidogenesis,0.2667057444314186,0.7475261257361849,0.810126582278481,0.8859839739236725,1.0,5/5,73.41%,AKR1C3;LDLR;SCARB1;PRKACA;ACOT1
232,prerank,Transcriptional misregulation in cancer,0.1938889458263594,0.7337158451214075,0.7912087912087912,0.8976889944226628,1.0,6/10,42.43%,H3-3A;HMGA2;EWSR1;HDAC1;BAIAP3;DDX5
233,prerank,Regulation of actin cytoskeleton,0.09206116857261436,0.7322322754763922,0.8222591362126246,0.8917536970078439,1.0,42/52,72.94%,FN1;ACTB;F2;GSN;PFN1;MYH9;ACTN1;EZR;ARPC4;RAC1;ACTR3;CFL1;ACTN4;IQGAP1;ARPC2;ROCK2;DIAPH1;MYH10;ARPC5;MSN;PFN2;MYH14;CDC42;VCL;ARPC3;KNG1;MYLK2;MAPK3;PPP1CA;PPP1CB;ARPC1B;ARPC5L;MAP2K1;CYFIP2;PDGFA;MYLK;ACTR2;ITGB1;MYL12A;NRAS;ITGA2;NCKAP1
234,prerank,Long-term depression,-0.22125545505796881,-0.7283674962163824,0.7864693446088795,0.8897705874914991,1.0,5/7,48.16%,GNAI2;MAPK1;NRAS;MAP2K1;MAPK3
235,prerank,Ether lipid metabolism,0.22593896713615017,0.7253179044166563,0.8148148148148148,0.8939027119402682,1.0,7/7,77.50%,PLA2G2A;PLA2G7;PAFAH1B1;ENPP2;PAFAH1B3;GAL3ST1;PLD3
236,prerank,Viral myocarditis,0.1907974044512915,0.7246270015489001,0.7992565055762082,0.8871581990218652,1.0,8/10,62.01%,ACTB;RAC1;HLA-A;PRF1;LAMA2;DAG1;ICAM1;HLA-C
237,prerank,Insulin resistance,0.1405788541051387,0.7186644882061559,0.82,0.8879302014049025,1.0,18/18,86.09%,PTPRF;PYGB;SLC2A1;AGT;PYGL;PCK2;GFPT1;PPP1CA;PPP1CB;GYS1;PTPN11;PTPA;RPS6KA3;PCK1;PRKAG1;STAT3;PPP1CC;PRKAA1
238,prerank,Gastric acid secretion,0.20746003051125878,0.7141598320750667,0.8191881918819188,0.8859460022003508,1.0,7/8,67.68%,ACTB;EZR;CALM1;ATP1A1;MYLK2;MYLK;PRKACA
239,prerank,Vibrio cholerae infection,-0.20003963072252823,-0.7113863877313028,0.8076923076923077,0.9057583415108698,1.0,5/8,40.97%,ATP6AP1;ATP6V1B2;PRKACA;ERO1A;ATP6V1A
240,prerank,Propanoate metabolism,-0.1657145700979642,-0.7112201083558558,0.8415178571428571,0.898782365098258,1.0,10/12,65.98%,SUCLA2;PCCA;PCCB;ACSS2;HADHA;ACAT2;ABAT;ACAT1;ACSS3;ECHS1
241,prerank,Drug metabolism,-0.13279140919513066,-0.7073262058066464,0.8589108910891089,0.8966947397679104,1.0,16/19,70.37%,CES1;GUSB;RRM2B;ITPA;DPYS;GSTM1;CMPK1;RRM1;DPYD;IMPDH2;GSTM2;GSTA1;GSTM3;GMPS;GSTP1;NME1
242,prerank,Citrate cycle (TCA cycle),0.14530259941933,0.6982461366239658,0.8194690265486726,0.8990315003963756,1.0,7/18,25.83%,CS;ACLY;MDH2;ACO1;IDH1;PCK2;ACO2
243,prerank,Leukocyte transendothelial migration,0.1284519111667131,0.6932785112765414,0.8650088809946714,0.89761590759226,1.0,18/22,70.08%,ACTB;RAP1B;ACTN1;EZR;RAC1;ACTN4;ROCK2;MSN;VASP;CDC42;VCL;VCAM1;CDH5;ICAM1;PTPN11;ITGB1;MYL12A;CTNNB1
244,prerank,Hypertrophic cardiomyopathy,0.1404958677685954,0.6854449394401975,0.8670212765957447,0.8991302667182065,1.0,17/17,86.09%,ACTB;TGFB1;LMNA;AGT;TPM1;CACNA2D1;TTN;LAMA2;DAG1;ITGB1;TPM4;ITGA2;ACE;TPM3;PRKAG1;ITGB3;PRKAA1
245,prerank,Sphingolipid metabolism,-0.20950704225352113,-0.6788386828992364,0.8619153674832962,0.9248190833556686,1.0,7/7,79.19%,SMPD1;GAL3ST1;GBA;NEU1;GLA;GLB1;PSAP
246,prerank,Type II diabetes mellitus,-0.21888930339807297,-0.6755628247773882,0.8592436974789915,0.9212395980208541,1.0,5/6,60.14%,MAPK1;HK2;HK1;MAPK3;PKLR
247,prerank,Porphyrin and chlorophyll metabolism,-0.20767637319042853,-0.6651262351140885,0.8574423480083857,0.9258544022739907,1.0,5/7,49.44%,GUSB;CPOX;CP;UROD;EPRS1
248,prerank,Glycosphingolipid biosynthesis,-0.1709753231492362,-0.6450269431997862,0.9094827586206896,0.9395646719337398,1.0,9/9,83.05%,ST3GAL1;ST3GAL6;HEXA;FUT3;NAGA;GLA;GLB1;B4GALT1;HEXB
249,prerank,AMPK signaling pathway,0.1281664033790909,0.6420881500201776,0.9233644859813084,0.9385212777172576,1.0,7/18,27.64%,EEF2;PPP2CA;FASN;RAB11B;PCK2;PPP2R1A;RAB14
250,prerank,Neurotrophin signaling pathway,-0.14427709288948448,-0.6410992765692533,0.9217391304347826,0.9360170352196618,1.0,7/13,38.22%,ARHGDIA;MAPK14;MAPK1;RPS6KA3;NRAS;PTPN11;MAP2K1
251,prerank,Proximal tubule bicarbonate reclamation,0.23153575615474803,0.6347553365402323,0.8928571428571429,0.9377792176519419,1.0,5/5,76.91%,GLUD1;PCK2;ATP1A1;MDH1;PCK1
252,prerank,Longevity regulating pathway,-0.17398410775110817,-0.6299592414128496,0.9190283400809717,0.9394182432722742,1.0,7/9,59.15%,PRKAA1;PRKAG1;NRAS;PRKACA;EIF4E;CAT;HDAC1
253,prerank,Chagas disease,0.14411579729896043,0.6126460781950557,0.9280442804428044,0.9489143654482544,1.0,5/13,26.24%,C3;TGFB1;PPP2CA;SERPINE1;PPP2R1A
254,prerank,PPAR signaling pathway,0.12837327055527226,0.6096906908397386,0.9295774647887324,0.9435904709652482,1.0,11/16,57.57%,APOA1;APOC3;PLTP;PCK2;ILK;LPL;APOA5;ANGPTL4;APOA2;HMGCS1;ME1
255,prerank,Yersinia infection,0.10698433628957489,0.5837243616168492,0.9395017793594306,0.955356783919598,1.0,21/22,85.15%,FN1;ACTB;ARPC4;RAC1;ACTR3;ARPC2;ROCK2;ARPC5;CDC42;ARPC3;MAPK3;ARPC1B;ARPC5L;MAP2K1;ACTR2;ITGB1;ARF6;RPS6KA3;MAPK1;MAPK14;SRC
256,prerank,Axon guidance,-0.08814585678665843,-0.581824263678679,0.9607390300230947,0.9690355188322668,1.0,17/29,48.45%,SRGAP2;RRAS;GNAI2;PLXNA1;SRC;MAPK1;SEMA7A;SEMA3F;PPP3CA;NRAS;MYL12A;ITGB1;PTPN11;SEMA3C;SEMA3A;MAPK3;SEMA4B
257,prerank,Autoimmune thyroid disease,-0.20691676436107853,-0.5657394491649642,0.9649122807017544,0.9709733997282136,1.0,5/5,79.43%,HLA-G;HLA-C;TG;PRF1;HLA-A
258,prerank,Chemical carcinogenesis,0.08897316537164163,0.553761683168516,0.9682274247491639,0.9655558009829367,1.0,29/31,85.15%,HSP90AB1;HSP90AA1;GSTA5;HSP90B1;GSTO1;KPNB1;PTGES3;GSTP1;EPHX1;CBR1;GSTM3;GSTA1;GSTM2;AKR1C2;SULT1A1;MAPK3;SULT2A1;MAP2K1;PRKACA;NRAS;GSTM1;RPS6KA3;SULT1A3;MAPK1;ARRB1;STAT3;VEGFA;STAT5B;SRC
259,prerank,Glycosaminoglycan degradation,-0.17067448680351907,-0.5122370527028972,0.9846153846153847,0.985546522131888,1.0,6/6,83.05%,GUSB;GNS;HEXA;HYAL1;GLB1;HEXB
